The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Jim Cramer, the host of Mad Money, recently revisited one of his core investment principles: "Nobody ever made a dime ...

Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...